EXG102-031 / Exegenesis Bio - LARVOL DELTA

A Study of EXG102-031 in Patients With wAMD (Everest) (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Exegenesis Bio | Active, not recruiting ➔ Completed

Trial completion • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU) (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Exegenesis Bio | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Long-term Follow up Study of EXG102-031 in Participants With wAMD (clinicaltrials.gov) - P=N/A | N=42 | Recruiting | Sponsor: Hangzhou Jiayin Biotech Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study of EXG102-031 in Patients With wAMD (Everest) (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Exegenesis Bio | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2024 ➔ Feb 2026

Enrollment closed • Trial primary completion date • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Long-term Follow up Study of EXG102-031 in Participants With wAMD (clinicaltrials.gov) - P=N/A | N=42 | Not yet recruiting | Sponsor: Hangzhou Jiayin Biotech Ltd

New trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Long-term Follow Up Study of EXG102-031 in Patients with WAMD (Everest LTFU) (clinicaltrials.gov) - P1 | N=12 | Enrolling by invitation | Sponsor: Exegenesis Bio

New P1 trial • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Subretinal Gene Therapy for Treatment of Retinal and Choroidal Vascular Diseases. (PubMed, Am J Ophthalmol) - "This review article discusses investigational subretinal gene therapies for retinal vascular diseases, including AVA-101, an adeno-associated viral (AAV) 2 vector expressing soluble vascular endothelial growth factor (VEGF) receptor 1, ABBV-RGX-314, an AAV8 vector expressing an anti-VEGF-A antibody fragment, and EXG102-031, an AAV8 vector expressing a recombinant protein that blocks VEGF family members and angiopoietin 2. In contrast, subretinal injection of some doses of ABBV-RGX-314 have shown evidence of controlling exudation and the maintaining vision, as well as safety and tolerability, leading to two ongoing pivotal trials comparing subretinal delivery of two different doses of ABBV-RGX-314 versus intravitreal injections of 0.5mg ranibizumab or 2mg aflibercept. These preliminary results are an encouraging and welcome development in the search for efficacious, long-duration treatments for retinal vascular diseases."

Gene therapy • Journal • Age-related Macular Degeneration • Gene Therapies • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders

Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond. (PubMed, Genes (Basel)) - "This manuscript reviews ongoing gene therapy clinical trials for these disorders, including ABBV-RGX-314, ixoberogene soroparvovec (ixo-vec), and 4D-150. ABBV-RGX-314 utilizes an adeno-associated virus (AAV) vector to deliver a transgene encoding a ranibizumab-like anti-VEGF antibody fragment, demonstrating promising results in Phase 1/2a and ongoing Phase 2b/3 trials...Other therapies reviewed include EXG102-031, FT-003, KH631, OLX10212, JNJ-1887, 4D-175, and OCU410. These therapies offer potential advantages of reduced treatment frequency and enhanced safety profiles, representing a paradigm shift in management towards durable and efficacious cellular-based biofactories. These advancements in gene therapy hold promise for improving outcomes in AMD and addressing the complex challenges of DME and DR, providing new avenues for the treatment of diabetic eye diseases."

Gene therapy • Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • VEGFC

A Study of EXG102-031 in Participants With wAMD (clinicaltrials.gov) - P1/2 | N=42 | Recruiting | Sponsor: Hangzhou Jiayin Biotech Ltd

New P1/2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study of EXG102-031 in Patients With wAMD (Everest) (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: Exegenesis Bio | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study of EXG102-031 in Patients With wAMD (Everest) (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Exegenesis Bio

Gene therapy • New P1 trial • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration